Wednesday, March 23, 2016
Stemedica International Presents at Geneva Springfield Alzheimer’s Conference in Athens, Greece
Stemedica International, SA, a leader in the development of innovative stem cell-based treatments for Alzheimer’s Disease announced today that its Chief Scientist, Tristan Bolmont, PhD, gave a presentation at the 14th International Athens / Springfield Symposium on Advances in Alzheimer Therapy on Saturday, March 12, 2016 in Athens, Greece. This prestigious symposium drew over 1000 participants from all over the world. Leading scientists discussed new targets and drugs for the treatment of Alzheimer’s disease and novel approaches to current therapy. Dr. Bolmont’s talk was titled, “Stem Cells for Alzheimer’s disease: Translation to Clinical Trials”.
“I was excited to share the latest pre-clinical research and clinical developments that Stemedica International has accomplished in the past year”, says Dr. Bolmont. “Our uniquely potent hypoxically-manufactured mesenchymal stem cells significantly reduce the levels of Abeta amyloidosis in both aged and young transgenic mice along with significant reductions in neuroinflammation. Biodistribution shows that our stem cells penetrate the blood-brain barrier and mechanism of action research indicates that beneficial changes in Abeta and neuroinflammation may be due to increases in certain Abeta degrading enzymes and decreases in certain pro-inflammatory cytokines. Clinically, Stemedica International is the first company in the United States to receive FDA approval for a Phase IIa clinical trial treating AD using stem cells.”
About Stemedica International S.A.
Stemedica International S.A. is a biotechnology company that develops therapeutic applications for the treatment and prevention of Alzheimer’s disease and vascular dementia. The company is a subsidiary of Stemedica Cell Technologies, Inc., a global biotechnology company that manufactures adult allogeneic stem cells. Stemedica International has the worldwide rights to manufacture and distribute the parent company’s allogeneic, ischemia-tolerant mesenchymal stem cell (itMSC) and ischemia-tolerant neural stem cell (itNSC) lines and stem cell factors for Alzheimer’s disease and vascular dementia indications. The company also has Swissmedic licenses to import, export and distribute Stemedica Cell Technologies’ cell lines worldwide for human use in approved clinical trials. Manufactured in compliance with cGMP standards, the stem cell lines have a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability. For more information, visit www.stemedica-intl.com.
Forward Looking Statements
This press release may contain forward-looking statements. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance and you are cautioned not to place undue reliance on these forward-looking statements. These statements reflect the views of Stemedica as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
Media and Business Contact
Stemedica International S.A.
+41 (0)78 794 7232